The future of health care

Health care is undergoing a digital transformation, speeded by the COVID-19 pandemic.

11 set 2020

The future of healthcare – in 60 seconds

  • The COVID-19 pandemic has inflicted massive economic damage on the health care industry;
  • However, developments in data analysis and digital connectivity are driving a digital transformation in health care;
  • Telemedicine has accelerated significantly because consumers have opted for the socially distanced safety, low cost, and ease of remote health services;
  • New digital technologies could speed the development of a COVID-19 vaccine and boost the genomic medicine sector;
  • We believe that the future of health care looks bright, particularly companies that are powering the digital transformation of the health care sector in areas like telemedicine, genomic medicine, and robotic-assisted surgery.

Typically, the health care sector remains resilient during tough economic times.

In the United States, health care employment actually grew during the Great Financial Crisis, offering a crucial offset as the rest of the economy faltered.

According to US Bureau of Labor Statistics, unemployment would have been 600,000 persons higher (at 9.2 million persons unemployed) at the start of 2010 were it not for employment growth in the health care sector.

What is the situation today?

The current health care crisis extends beyond the pandemic.

While it might seem paradoxical, the COVID-19 pandemic has inflicted massive economic damage on the health care industry. Hospital systems have suffered enormous financial strains as a result of the onslaught of COVID-19 hospitalizations, procedure cancellations (electoral procedures had become increasingly important to hospitals' bottom line), and lower non-COVID-19 emergency room traffic.

As governments have imposed lockdowns, we have seen job losses in dentists and physician's offices, as well as physical therapy clinics that have paralleled losses in the overall service sector

Digital transformation offers a way forward

Despite the magnitude of health care supply and demand destruction, we see opportunities in the digital transformation of health care.

Although traditionally slow to adopt new digital technologies, we see faster adoption as systems around the world struggle with rising costs and the constraints paused by COVID-19.

Telemedicine, genomic medicine, and robotic-assisted surgery are just three areas that offer new services that could meaningfully affect patient outcomes.

Although traditionally slow to adopt new digital technologies, we see faster adoption as systems around the world struggle with rising costs and the constraints paused by COVID-19.

At its core are two main drivers:

  • developments in data analysis (from increased computing power – for instance genomic medicine is a big data science), and
  • connectivity (permitting care outside hospitals).

Telemedicine – global virtual care

The adoption of telemedicine has accelerated significantly, helped by a much more accommodative regulatory environment ushered by the current crisis. Consumers have increasingly opted for the socially distanced safety, low cost, and ease of remote telemedicine.

In March, reported that several providers started offering coronavirus assessments online, using telemedicine platforms, when the COVID-19 crisis started to take hold in Europe and the United States. The objective was to screen patients during a telehealth visit to detect potential symptoms and to keep patients who don’t need to be hospitalized away from waiting rooms.

Growth of telehealth visits during COVID-19 - % weekly increases, vs pre-COVID-19 baseline

Source: IQVIA – medical claim data analysis, 2020. Baseline: average of visits for period 1/10/2020-2/28/2020.

The percentage increase in telehealth visits in the United States per week from March 6, 2020 to April 3, 2020 compared with the baseline number of visits before the outbreak of COVID-19, according to IQVIA

In a bull scenario, telemedicine could radically disrupt ambulatory care delivery by scaling accessibility at lower delivery cost than conventional offices.

Beyond the telehealth visit described above, telemedicine could become even more effective with the growing availability of wearable sensors that could report on blood chemistry, blood pressure, and other important metrics.

Telemedicine: market size (USD bn), 2014-2025 (f)

Source: UBS GWM CIO, Frost & Sullivan, Statista, Bloomberg Intelligence, March 2020

UBS forecasts on the growth of produced data in the US and China in zettabytes between 2014 and 2015

Genomic medicine - mastering biology to advance human health

New digital technologies, already transforming drug discovery and therapeutic development, could speed the development of a COVID-19 vaccine.

Representing the culmination of two decades of progress, new sequencing tools have given researchers quick access to COVID-19’s RNA sequence, lending crucial insight into how the virus operates.

Advances in robotics, cloud computing, and bioinformatics facilitate faster vaccine candidate development with greater automation and parallelization than could have been possible using conventional techniques.

Over the longer term, we see great potential for companies that can combine biology, software, computing and chemistry to advance the medical state of the art, with key application areas including gene expression, immunology, and DNA sequencing.

The future of health care looks bright

We believe that the future of health care looks bright and it starts now with companies that are powering the digital transformation of the health care sector. This sector is notoriously slow in adapting to new technologies, but COVID-19 may prove to be a watershed moment. So contact us now to learn more about how to invest in digital transformation.

Latest equity insights


Asset Management services and solutions in your location

Please select your region


For further information on what we can offer you, please get in touch.

Important legal information

To proceed, please confirm that you are a professional / qualified / institutional client and investor.

Views and opinions expressed are presented for informational purposes only and are a reflection of UBS Asset Management’s best judgment at the time a report or other content was compiled. UBS specifically prohibits the redistribution or reproduction of this material in whole or in part without the prior written permission of UBS and UBS accepts no liability whatsoever for the actions of third parties in this respect. The information and opinions contained in the content of this webpage have been compiled or arrived at based upon information obtained from sources believed to be reliable and in good faith but no responsibility is accepted for any errors or omissions. All such information and opinions are subject to change without notice but any obligation to update or alter forward-looking statement as a result of new information, future events, or otherwise is disclaimed. Source for all data/charts, if not stated otherwise: UBS Asset Management.
Any market or investment views expressed are not intended to be investment research. Materials have not been prepared to address requirements designed to promote the independence of investment research and are not subject to any prohibition on dealing ahead of the dissemination of investment research. The information contained in this webpage does not constitute a distribution, nor should it be considered a recommendation to purchase or sell any particular security or fund. The materials and content provided will not constitute investment advice and should not be relied upon as the basis for investment decisions. As individual situations may differ, clients should seek independent professional tax, legal, accounting or other specialist advisors as to the legal and tax implication of investing. Plan fiduciaries should determine whether an investment program is prudent in light of a plan's own circumstances and overall portfolio. A number of the comments in the content of this webpage are considered forward-looking statements. Actual future results, however, may vary materially. Past performance is no guarantee of future results. Potential for profit is accompanied by possibility of loss. 
© UBS 2021 The key symbol and UBS are among the registered and unregistered trademarks of UBS.